The purpose of this study is to demonstrate that long-term treatment (up to six years) with
telbivudine or telbivudine plus adefovir results in the regression in liver inflammation and
fibrosis/cirrhosis.
Phase:
Phase 4
Details
Lead Sponsor:
Nanfang Hospital of Southern Medical University
Collaborators:
Major Science and Technology Special Project of China Twelfth-Five-Year Project Novartis